Please use this identifier to cite or link to this item: http://hdl.handle.net/10400.17/3092
Title: Safe Use of Infliximab for the Treatment of Severe Perianal Crohn's Disease After Diagnosis and Treatment of Lymphoma
Author: Bernardes, C
Russo, P
Carvalho, D
Saiote, J
Ramos, J
Keywords: Adult
Anti-Inflammatory Agents
Crohn Disease
Gastrointestinal Agents
Humans
Infliximab
Lymphoma, Large B-Cell, Diffuse
Male
Prednisolone
Tumor Necrosis Factor-alpha
CHLC GAS
Issue Date: Feb-2018
Publisher: Springer
Citation: Clin J Gastroenterol. 2018 Feb;11(1):48-52.
Abstract: Inflammatory bowel disease is associated with an increased likelihood of developing lymphoma. However, it is still controversial if this risk may be attributed to the disease itself or rather represents an effect of immunosuppressive treatment. Although tumor necrosis factor alpha (TNFα) is a key cytokine for cancer immunosurveillance, the potential relationship between anti-TNFα agents and the pathogenesis of lymphoproliferative disorders remains unclear. Here, we describe the case of a patient with severe perianal Crohn's disease, treated with infliximab monotherapy, whose unusual presentation with acute groin pain required surgical intervention and led to the diagnosis of diffuse large B-cell lymphoma. However, 10 months after this episode, treatment with infliximab was restarted because the patient continued with refractory and disabling perianal disease. Currently, with a follow-up of 36 months, under infliximab 10 mg/kg every 4 weeks, he maintains mild perianal Crohn's disease and persists in sustained clinical and imaging remission of the lymphoproliferative disorder.
Peer review: yes
URI: http://hdl.handle.net/10400.17/3092
DOI: 10.1007/s12328-017-0802-8
Appears in Collections:GAS - Artigos

Files in This Item:
File Description SizeFormat 
Clin J Gastro 2018 48.pdf1,06 MBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.